Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This meta-analysis has been conducted to determine the risk of elevated transaminases associated with immune checkpoint inhibitors use in patients with cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Expert Opin Drug Saf

Title: Expert opinion on drug safety

Publisher: Informa Healthcare

ISSN (Electronic): 1744-764X

ISSN (Print): 1474-0338

Publication date (Electronic): Oct 2015

Volume: 14

Issue: 10

Affiliations

[1 ] a 1 Ain Shams University, Clinical Oncology Department , Cairo, Egypt +33028656 ; omar.abdelrhman@med.asu.edu.eg.

[2 ] b 2 Ain Shams University, Medical Microbiology and Immunology Department , Cairo, Egypt.

Article

DOI: 10.1517/14740338.2015.1085969

PubMed ID: 26394770

SO-VID: df4a4c8a-f764-4863-ba94-83e42542752c

History

Keywords: pembrolizumab,aspartate aminotransferase,ipilimumab,nivolumab,alanine aminotransferase

Data availability:

Keywords: pembrolizumab, aspartate aminotransferase, ipilimumab, nivolumab, alanine aminotransferase

Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Read this article at

Abstract

Related collections

Road 2 Open Meta

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 25